Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents

被引:39
作者
Hoellman, DB
Lin, GR
Jacobs, MR
Appelbaum, PC
机构
[1] Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA
[2] Case Western Reserve Univ, Cleveland, OH 44106 USA
关键词
D O I
10.1093/jac/43.5.645
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
An agar dilution MIC method was used to test the activity of gatifloxacin, a new broad-spectrum fluoroquinolone, compared with ciprofloxacin, levofloxacin, sparfloxacin, trovafloxacin, amoxycillin, cefuroxime, ceftriaxone and clarithromycin against 71 penicillin-susceptible, 81 penicillin-intermediate and 55 penicillin-resistant pneumococci. Quinolone activity was unaffected by penicillin susceptibility, with MIC50/MIC(90)s (mg/L) of 0.25/0.5 for gatifloxacin; 1/2 for ciprofloxacin; 1/2 for levofloxacin; 0.25/0.5 far sparfloxacin; 0.125/0.25 for trovafloxacin. beta-Lactam and clarithromycin MICs rose with those of penicillin G; MIC50/MIC90 values (mg/L) for penicillin-susceptible, -intermediate and -resistant strains were: 0.03/0.06, 0.25/1, 2/4 for penicillin G; 0.03/0.03, 0.125/1, 2/4 for amoxycillin; 0.03/0.125, 0.5/4, 8/16 for cefuroxime; 0.03/0.03, 0.25/0.5, 2/4 for ceftriaxone; 0.03/0.06, 0.03/>64, 1/>64 for clarithromycin. Time-kill testing of four penicillin-susceptible, four -intermediate and four -resistant strains showed that levofloxacin at the MIG, gatifloxacin and sparfloxacin at 2 x MIC, and trovafloxacin and ciprofloxacin at 4 x MIC, were bactericidal (99.9% killing) for all strains after 12 h and 24 h. By contrast, amoxycillin, cefuroxime and ceftriaxone showed bactericidal activity after 24 h against all strains at 4, 8 and 4 x MIC, respectively. Against ten organisms with clarithromycin MICs of 0.03-4.0 mg/L, clarithromycin was bactericidal against seven strains at 8 x MIC after 24 h. Quinolones showed mote rapid killing at lower concentrations and earlier time periods than did beta-lactams and clarithromycin.
引用
收藏
页码:645 / 649
页数:5
相关论文
共 23 条
[1]   ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW [J].
APPELBAUM, PC .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :77-83
[2]   Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [J].
Bauernfeind, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :639-651
[3]   PENICILLIN-RESISTANT STREPTOCOCCUS-PNEUMONIAE IN ACUTE OTITIS-MEDIA - RISK-FACTORS, SUSCEPTIBILITY PATTERNS AND ANTIMICROBIAL MANAGEMENT [J].
BLOCK, SL ;
HARRISON, CJ ;
HEDRICK, JA ;
TYLER, RD ;
SMITH, RA ;
KEEGAN, E ;
CHARTRAND, SA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1995, 14 (09) :751-759
[4]   EMERGENCE OF DRUG-RESISTANT PNEUMOCOCCAL INFECTIONS IN THE UNITED-STATES [J].
BREIMAN, RF ;
BUTLER, JC ;
TENOVER, FC ;
ELLIOTT, JA ;
FACKLAM, RR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1831-1835
[5]   Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study [J].
Doern, GV ;
Brueggemann, A ;
Holley, HP ;
Rauch, AM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1208-1213
[6]   MANAGEMENT OF PENICILLIN-RESISTANT PNEUMOCOCCAL INFECTIONS [J].
FRIEDLAND, IR ;
ISTRE, GR .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1992, 11 (06) :433-435
[7]  
FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607
[8]   ANTIBACTERIAL PROPERTIES OF AM-1155, A NEW 8-METHOXY QUINOLONE [J].
HOSAKA, M ;
KINOSHITA, S ;
TOYAMA, A ;
OTSUKI, M ;
NISHINO, T .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (02) :293-301
[9]   INVITRO AND INVIVO ANTIBACTERIAL ACTIVITIES OF AM-1155, A NEW 6-FLUORO-8-METHOXY QUINOLONE [J].
HOSAKA, M ;
YASUE, T ;
FUKUDA, H ;
TOMIZAWA, H ;
AOYAMA, H ;
HIRAI, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (10) :2108-2117
[10]   TREATMENT AND DIAGNOSIS OF INFECTIONS CAUSED BY DRUG-RESISTANT STREPTOCOCCUS-PNEUMONIAE [J].
JACOBS, MR .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :119-127